# Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Study · id `cardio:ct-nct07684144` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07684144](<https://clinicaltrials.gov/study/NCT07684144>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07684144

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 950 participants.

## Technical summary

Registry record NCT07684144. Randomized; double masking; primary purpose treatment. Start 2026-07-29 (actual); primary completion 2027-12-26 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 950 participants (planned count; ClinicalTrials.gov record NCT07684144, source copy `cardio:ctgov-nct07684144-2026-10-05`, retrieved 2026-10-26)
- Started: 2026-07-29 (actual) (ClinicalTrials.gov record NCT07684144, source copy `cardio:ctgov-nct07684144-2026-10-05`, retrieved 2026-10-26)
- Primary completion: 2027-12-26 (anticipated) (ClinicalTrials.gov record NCT07684144, source copy `cardio:ctgov-nct07684144-2026-10-05`, retrieved 2026-10-26)
- Completion: 2028-03-19 (anticipated) (ClinicalTrials.gov record NCT07684144, source copy `cardio:ctgov-nct07684144-2026-10-05`, retrieved 2026-10-26)
- Countries: United States; Canada; Japan; Puerto Rico; United Kingdom (ClinicalTrials.gov record NCT07684144, source copy `cardio:ctgov-nct07684144-2026-10-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07684144-2026-10-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Condition: Obesity
- Condition: Overweight
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Maridebart Cafraglutide
- Intervention (Drug): Placebo
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: dcd70188a296bdd1c9352232ad1e635cf8836067f6562420766c7a85f95829ae
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
